Abstract
Most long-term diabetic patients develop microvascular diseases such as retinopathy, nephropathy and neuropathy. Although tight control of blood glucose greatly reduces the incidence of these complications, a significant fraction of diabetic patients with good glycemic control still develop these diseases. Therefore, it is imperative to understand the underlying mechanisms of these diseases such that effective treatment or preventive methods can be developed to augment euglycemic control. In animal studies, there is strong evidence that aldose reductase, the first and rate-limiting enzyme of the polyol pathway that converts glucose to fructose, plays a key role in the pathogenesis of microvascular complications. However, clinical trials of the aldose reductase inhibitors were disappointing and several pharmaceutical companies had abandoned the development of this line of drugs. In this review, the potential pathogenic mechanisms of the polyol pathway are presented, the evidence for the involvement of the polyol pathway in diabetic complications summarized, and the reasons for the unimpressive results of the clinical trials of the aldose inhibitors discussed. It appears that renewed efforts to develop aldose reductase inhibitors for the treatment and prevention of diabetic complications are warranted.
Keywords: aldose reductase, polyol pathway, diabetic complications, microvascular
Current Drug Targets
Title: Aldose Reductase in Diabetic Microvascular Complications
Volume: 6 Issue: 4
Author(s): S. S.M. Chung and S. K. Chung
Affiliation:
Keywords: aldose reductase, polyol pathway, diabetic complications, microvascular
Abstract: Most long-term diabetic patients develop microvascular diseases such as retinopathy, nephropathy and neuropathy. Although tight control of blood glucose greatly reduces the incidence of these complications, a significant fraction of diabetic patients with good glycemic control still develop these diseases. Therefore, it is imperative to understand the underlying mechanisms of these diseases such that effective treatment or preventive methods can be developed to augment euglycemic control. In animal studies, there is strong evidence that aldose reductase, the first and rate-limiting enzyme of the polyol pathway that converts glucose to fructose, plays a key role in the pathogenesis of microvascular complications. However, clinical trials of the aldose reductase inhibitors were disappointing and several pharmaceutical companies had abandoned the development of this line of drugs. In this review, the potential pathogenic mechanisms of the polyol pathway are presented, the evidence for the involvement of the polyol pathway in diabetic complications summarized, and the reasons for the unimpressive results of the clinical trials of the aldose inhibitors discussed. It appears that renewed efforts to develop aldose reductase inhibitors for the treatment and prevention of diabetic complications are warranted.
Export Options
About this article
Cite this article as:
Chung S.M. S. and Chung K. S., Aldose Reductase in Diabetic Microvascular Complications, Current Drug Targets 2005; 6 (4) . https://dx.doi.org/10.2174/1389450054021891
DOI https://dx.doi.org/10.2174/1389450054021891 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Methylglyoxal in Diabetic Cardiovascular and Kidney Diseases: Insights from Basic Science for Application into Clinical Practice
Current Pharmaceutical Design Selected Heterocyclic Compounds as Antioxidants. Synthesis and Biological Evaluation
Current Topics in Medicinal Chemistry The Heat Stress Response and Diabetes: More Room for Mitochondrial Implication
Current Pharmaceutical Design New Hope for the Diagnosis and Therapy of Alzheimers Disease
Protein & Peptide Letters Inhibition of Human Serine Racemase, an Emerging Target for Medicinal Chemistry
Current Drug Targets Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Diabetes
Current Pharmaceutical Design Current Antioxidant Molecular Therapies for Oxidative Stress-Related Ailments
Current Gene Therapy Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders
Current Drug Targets Applications of iTRAQ and TMT Labeling Techniques to the Study of Neurodegenerative Diseases
Current Protein & Peptide Science Rhodanine as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Induced Pluripotent Stem Cell-Based Studies of Parkinson's Disease: Challenges and Promises
CNS & Neurological Disorders - Drug Targets Medical Treatment of Symptomatic Diabetic Neuropathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Protein Kinase C Isozymes: Memory Therapeutic Potential
Current Drug Targets - CNS & Neurological Disorders Nonfasting Hyperlipidemia and Cardiovascular Disease
Current Drug Targets Detrimental Effects of Hyperglycemia in Acute Coronary Syndromes: from Pathophysiological Mechanisms to Therapeutic Strategies
Mini-Reviews in Medicinal Chemistry Glucose Lowering Activity of Aqueous Ammodaucus leucotrichus Extract in Diabetic Rats
Cardiovascular & Hematological Disorders-Drug Targets Biphasic (Premix) Insulin Analogs in Type 2 Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Periodontal Disease and Potential Association with Systemic Diseases and Conditions (Mini-review)
Applied Clinical Research, Clinical Trials and Regulatory Affairs Meet the Editorial Board:
Technology Transfer and Entrepreneurship (Discontinued) Chemistry and Biology of Indoles and Indazoles: A Mini-Review
Mini-Reviews in Medicinal Chemistry